Patient who received the heart of a genetically engineered pig died, hospital says –

Patient who received the heart of a genetically engineered pig died, hospital says –
Transplant surgeon Bartley P. Griffith Jr., David Bennett Sr., who received a heart implant from a genetically engineered pig in January. left with. According to the University of Maryland Medical Center, Bennett, 57, died on March 8, 2022. (University of Maryland School of Medicine / AFP / Getty Images)

Officials from the University of Maryland Medical Center said David Bennett Sr., the first person in the world to receive a genetically engineered pig heart, died on Tuesday.

Bennett had a groundbreaking transplant on January 7th. The cause of death in the hospital was not disclosed, but Bennett is said to have gotten worse a few days ago. Bennett is said to be receiving palliative care and was able to communicate with his family in his final hours.

Bennett “turned out to be a brave and noble patient who fought to the end,” said Bartley P. Griffith Jr., a heart transplant surgeon. “Mr. Bennett is known to millions of people around the world for his courage and his will to live.”

Bennett’s death is a setback for the field of accelerated xenograft, the process of transplanting organs from one species to another. Recent advances, including Bennett’s surgery and kidney transplantation in brain-dead people at NYU Langone Health and the University of Alabama at Birmingham, have been made possible by new technologies. Among them is CRISPR, a gene-editing tool recognized for the 2020 Nobel Prize in Chemistry. Organs are modified to be less alien to humans, reducing their chances of rejection.

Doctors hope that the use of genetically modified animal organs will eliminate the current shortage of organs for transplantation.

The need is merciless. More than 100,000 patients are on the national transplant waiting list. seventeen of them die Every day I wait for donor organs.

Suffering from heart failure and an irregular heartbeat, Bennett was deemed ineligible for a normal human heart transplant. The hospital said it accepted an ongoing experimental procedure with “unknown risks and benefits”. The Food and Drug Administration granted emergency clearance for the operation on December 31. It was a week later.

Xenotransplantation, which involves raising genetically modified pigs to provide organs that humans are unlikely to deny, has caused concern among animal rights activists and is closely followed by ethics experts.

Some scientists, particularly those working in the public health field, believe that large investments in xenotransplantation are wrong. They say the money should be allocated to prevent and treat chronic conditions and behaviors that cause some people’s organ replacement, such as diabetes, hypertension, obesity and smoking.

Bennett’s surgery became controversial for another reason.

Shortly after the operation, The Post reported that Bennett was tried for stabbing a man seven times in 1988, leaving him paralyzed. A jury acquitted Bennett of attempted murder, but found him guilty of carrying a battery and a concealed weapon. He was sentenced to 10 years in prison and served six.

The victim, Edward Schumacher, spent 19 years in a wheelchair, suffered a stroke in 2005 and died two years later at the age of 40, according to The Post. In January, officials from the University of Maryland Medical Center declined to say whether they knew of Bennett’s criminal record.

Second Chance Ethics: A pig heart transplant patient stabbed a man seven years ago

The hospital said Wednesday that Bennett’s heart transplant was initially successful and showed no signs of rejection. She did physical therapy and watched the Super Bowl. He was hospitalized the moment the video weakened Bennett, who, in a hospital bed, spoke a few words to his therapist saying, “America is beautiful.”

Before modified porcine organs are widely available to humans by xenograft, the safety and efficacy of the procedure must be tested in clinical trials.

With the exception of Bennett’s surgery, which the FDA granted emergency clearance under the Compassionate Use Statement, the latest kidney transplant was a preclinical study of people who died in the brain.

James Locke, director of the University of Alabama Birmingham Compatible Kidney Transplant Program, said he hopes to pass the first phase of clinical trials this year, usually the first phase to test for safety in humans. He and his team published a kidney transplant performed in September in the American Journal of Transplantation; this has provided ethicists and scientists with information crucial to the advancement of the field.

A spokesperson for the University of Maryland Medical Center said Wednesday that Bennett’s medical team was investigating the cause of death and plans to submit their findings to a peer-reviewed journal. They are also planning future clinical trials under the guidance of the FDA.

Mohammed M. Mohiudin, Professor of Surgery and Scientific Director of the University Program of Cardiac Xenotransplantation. Maryland School of Medicine. “We are optimistic and plan to continue our work in future clinical trials.”

Source: Washington Post